Advanced search
Publication Cover
Modern Rheumatology Volume 23, 2013 - Issue 2
Journal homepage
114
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

Naoto YokogawaDepartment of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8524, JapanCorrespondence[email protected]
,
Akiko TanikawaDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan
,
Masayuki AmagaiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan
,
Yukihiko KatoDepartment of Dermatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
,
Yoko MomoseDepartment of Dermatology, St. Luke’s International Hospital, Tokyo, Japan
,
Satoru AraiDepartment of Dermatology, St. Luke’s International Hospital, Tokyo, Japan
,
Hikaru EtoDepartment of Dermatology, St. Luke’s International Hospital, Tokyo, Japan
,
Takaharu IkedaDepartment of Dermatology, Wakayama Medical University, Wakayama, Japan
&
Fukumi FurukawaDepartment of Dermatology, Wakayama Medical University, Wakayama, Japan
 show all
Pages 318-322 | Received 02 Mar 2012, Accepted 16 Apr 2012, Published online: 02 Jan 2014

REFERENCES

  • Yokogawa N. Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/anti-rheumatic drugs; 10. Hydroxychloroquine. Nihon Naika Gakkai Zasshi. 2011;100:2960-5 (in Japanese).
  • Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, OkadaM. Hydroxychloroquine in Japan: a newly rising sun. J Rheuma-tol. 2012 (in press).
  • Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125:889–94.
  • Yokogawa N, Kato Y, Sugii S, Inada S. Response to hydroxy-chloroquine in Japanese patients with systemic lupuserythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2011 [Epub ahead of print].
  • Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol. 2011 [Epub ahead of print].
  • Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis. 1982;8:207–18.
  • Sontheimer RD, McCauliffe DP. Lupus-specific skin disease (cutaneous LE). In: Wallace DJ, Hahn WB, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 576–620.
  • Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147:203–8.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum. 1997;40:1725.
  • Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved dis-criminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin dis-eases. Arch Dermatol. 1997;133:1433–40.
  • Albrecht J, Werth VP. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 2010;19:1137–43.
  • Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.
  • Dubois E. Antimalarials in the management of discoid and sys-temic erythematosus. Semin Arthritis Rheum. 1978;8:33–51.
  • Tsuchida T. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev. 2009;8:453–5.
  • Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2011 [Epub ahead of print].
  • Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to anti-malarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145:244–8.
  • Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges. 2010;8:829–44.
  • Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:20–8.
  • Wolfe F, Marmor MF. Rates and predictors of hydroxychloro-quine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62:775–84.
  • Marmor MF, Kellner U, Lai TY, Lyons JS, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmol-ogy. 2011;118:415–22.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.